Form 8-K

8-K — Stereotaxis, Inc.

Accession: 0001493152-26-033405

Filed: 2026-07-16

Period: 2026-07-15

CIK: 0001289340

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001289340

2026-07-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT PURSUANT

SECTION 13 OR 15(D) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of report (Date of earliest event reported): July 15, 2026

STEREOTAXIS,

INC.

(Exact

Name of Registrant as Specified in Its Charter)

Delaware

(State

or Other Jurisdiction of Incorporation)

001-36159

94-3120386

(Commission

File Number)

(IRS

Employer Identification No.)

710

North Tucker Boulevard, Suite 110, St. Louis, Missouri

63101

(Address

of Principal Executive Offices)

(Zip

Code)

(314)

678-6100

(Registrant’s

Telephone Number, Including Area Code)

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act: ☐

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

STXS

NYSE

American LLC

Item

8.01. Other Events

Acquisition

of Robocath and Related Risk Factors

previously announced, on July 7, 2026, Stereotaxis, Inc. (the “Company”) completed its acquisition (the “Acquisition”)

of shares and other securities collectively representing 100% of the share capital and voting power of Robocath, a French société

par actions simplifiée, pursuant to that certain Share Sale Agreement, dated as of April 14, 2026, by and among the Company, Robocath,

the shareholders of Robocath and an individual serving as manager.

The

Company hereby incorporates by reference herein (i) certain risk factors relating to the Acquisition included in the Company’s

Registration Statement on Form S-3, filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 15, 2026,

which are included as Exhibit 99.1 hereto (the “Supplemental Risk Factors”) and (ii) the agreements filed as exhibits thereto:

the Share Sale Agreement, the Joinder Agreement thereto, the Form of Purchaser Warrant and the Resale Organization Agreement, filed as

Exhibits 2.1, 2.2, 4.1 and 10.1 hereto, respectively. The Supplemental Risk Factors and incorporated agreements supplement the risk factor

and other disclosures contained in the Company’s periodic reports filed with the SEC pursuant to the Securities Exchange Act of

1934, as amended, including in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with

the SEC on March 12, 2026, as amended by the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025,

filed with the SEC on April 3, 2026, as revised or supplemented by the Company’s Quarterly Report on Form 10-Q for the fiscal quarter

ended March 31, 2026, filed with the SEC on May 13, 2026.

Item

9.01. Financial Statements and Exhibits

(d)

Exhibits

2.1#†

Share Sale Agreement, dated as of April 14, 2026, by and among the Company, Robocath, the securityholders of Robocath party thereto, and Philippe Bencteux, as Manager, incorporated by reference to the Registration Statement on Form S-3 filed with the SEC on July 15, 2026, at Exhibit 2.1.

2.2†

Joinder Agreement, dated as of July 7, 2026, by and among European Investment Bank, the Registrant, Philippe Bencteux and Supernova Invest, relating to the Share Sale Agreement dated as of April 14, 2026, incorporated by reference to the Registration Statement on Form S-3 filed with the SEC on July 15, 2026, at Exhibit 2.2.

4.1

Form of Purchaser Warrant, incorporated by reference to the Registration Statement on Form S-3 filed with the SEC on July 15, 2026, at Exhibit 4.3.

10.1

Resale Organization Agreement, dated as of July 7, 2026, by and among the Company and the securityholders of Robocath party thereto, incorporated by reference to the Registration Statement on Form S-3 filed with the SEC on July 15, 2026, at Exhibit 10.1.

99.1

Supplemental Risk Factors.

104

Cover

Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

This

filing excludes certain schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K, which the Company agrees to furnish

supplementally to the Securities and Exchange Commission upon request; provided, however, that the Company may request confidential

treatment for any schedules or exhibits so furnished.

†

permitted by Regulation S-K, Item 601(b)(2)(ii) of the Securities Exchange Act of 1934, as amended, certain confidential portions

of this exhibit have been redacted from the publicly filed document.

Cautionary

Statement Regarding Forward-Looking Statements

This

Current Report on Form 8-K (including the Supplemental Risk Factors incorporated herein) includes statements that may constitute “forward-looking”

statements, usually containing the words “believe”, “estimate”, “project”, “expect” or

similar expressions. These forward-looking statements include without limitation statements regarding the recently completed acquisition

of Robocath, the anticipated financial performance of Stereotaxis and Robocath related thereto, including the anticipated benefits expected

from the acquisition, the potential strategic implications as a result of the acquisition, and the potential for achievement of the regulatory

and commercial milestones that would trigger contingent payments in the transaction. Forward-looking statements inherently involve risks

and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include,

but are not limited to, uncertainties involving the following: the ability of Stereotaxis to successfully integrate Robocath’s

operations, and continue the commercialization, development and sales of Robocath’s products and services, and disruption of Robocath’s

or Stereotaxis’s current plans and operations as a result thereof; the ability of Robocath or Stereotaxis to retain and hire key

personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the proposed transaction;

the ability of Stereotaxis to implement its plans, forecasts and other expectations with respect to Robocath’s business following

the completion of the transaction and realize additional opportunities for growth and innovation; the ability of Stereotaxis to realize

the anticipated benefits from the transaction in the anticipated amounts or within the anticipated timeframes or at all; the ability

to maintain relationships with Stereotaxis’s and Robocath’s respective employees, customers, other business partners and

governmental authorities; and the other risks discussed in the Company’s periodic and other filings with the Securities and Exchange

Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions

or changes after the date of this release. Additional information will also be set forth in future filings that we make with the SEC

from time to time. All forward-looking statements in this Current Report (including the Supplemental Risk Factors incorporated herein)

are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements

provided to reflect events that occur or circumstances that exist after the date on which they were made. There can be no assurance that

the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other

commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

STEREOTAXIS,

INC.

Date:

July 15, 2026

By:

/s/

Kimberly Peery

Name:

Kimberly

Peery

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

RISK

FACTORS

Risks

Related to our Recently Completed Acquisition of Robocath

may be unable to successfully integrate Robocath into our business and may fail to realize any or all of the anticipated benefits of

the acquisition, or those benefits may take longer to realize than expected.

Prior

to the completion of our acquisition of Robocath, both companies previously operated independently and manufactured different products.

The success of the acquisition will depend, in part, on our ability to (i) successfully integrate Robocath’s businesses into Stereotaxis,

(ii) successfully manufacture, commercialize, develop and sell Robocath’s robotic systems and next-generation interventional medical

devices and related products, and (iii) realize the anticipated benefits, including synergies, cost savings, growth and innovation opportunities

and operational efficiencies, from the Acquisition, all in a manner that does not materially disrupt existing customer, supplier and

employee relations. If we are unable to achieve these objectives within the anticipated time frame, or at all, the anticipated benefits

may not be realized fully or at all, or may take longer to realize than expected, and the value of our common stock may decline.

The

integration of Robocath into our business may result in material challenges, including, without limitation:

●

the

diversion of management’s attention from ongoing business concerns relating to our historical business and any resulting disruption

to our current plans and operations;

●

managing

a more complex combined business;

●

expanding

operations to manufacture Robocath’s robotic systems and associated disposable products and overcoming our lack of manufacturing

experience related to such products;

●

maintaining

employee morale, retaining key Robocath employees and the possibility that the integration process and organizational changes may

adversely impact the ability to maintain employee relationships;

●

transitioning

and maintaining business and operational relationships of Robocath, including suppliers, collaboration partners, employees and other

counterparties;

●

risks

related to retaining Robocath’s existing customers, including managing existing contracts with and any disputes with such customers;

●

the

integration process not proceeding as expected, including due to a possibility of faulty assumptions or expectations regarding the

integration process or Robocath’s operations;

●

risks

related to litigation, disputes, investigations or other events that could increase our expenses, result in liability or require

that we take other action;

●

consolidating

corporate, administrative and compliance infrastructures and eliminating duplicative operations;

●

communication

and logistical challenges associated with coordinating activities and maintaining consistent operational standards across widely-different

locations, separated by both geography and time zones;

●

unanticipated

issues in integrating information technology, communications and other systems;

●

unforeseen

expenses, costs, liabilities or delays associated with the Acquisition or the integration;

●

complying

with diverse and unfamiliar foreign laws or regulatory requirements, or unexpected changes to those laws or requirements, including

healthcare-specific regulatory regimes applicable to Robocath’s business in France and other jurisdictions, including managing

relationships with our regulators or other governmental authorities;

●

increased

costs and monitoring of compliance with other laws and regulatory requirements to which our business activities abroad are currently

subject, such as the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws with a significant anti-corruption

intent in France and other foreign countries, in which we and Robocath operate;

●

differing

payor reimbursement regimes, governmental payors and price controls applicable to medical devices in foreign markets;

●

managing

any competitive responses to the Acquisition;

●

compliance

with French corporate law applicable to Robocath, with which we are not familiar; and

●

cultural

differences in the conduct of business.

Many

of these factors are outside of our control, and any one of them could result in delays, increased costs, decreases in the amount of

expected cost savings or synergies and diversion of management’s time and energy, which could materially affect our financial position,

results of operations and cash flows.

The

Robocath acquisition will not be accretive to us and will increase our operating losses.

Although

we consider the acquisition of Robocath as complementary to our existing business, Robocath has sustained historical operating losses,

and we expect that it will continue to incur operating losses and negative cash flows in the coming few years. We may be required to

fund Robocath’s ongoing operations for the foreseeable future. For example, we extended operating loans to Robocath of $1.1 million

between signing of the Share Sale Agreement and the acquisition closing, which loans were repaid at closing and reduced the amount of

the Upfront Stock Consideration we paid to Robocath’s equityholders. Accordingly, the Robocath acquisition will not be accretive

to us and will increase our operating losses and negatively impact our results of operations on a consolidated basis in the near term.

While we have plans to improve Robocath’s operating results primarily through leveraging our commercial organization to grow revenue

of their next-generation system, we may not be successful in doing so in the near term or at all.

Our

future results may be adversely impacted if we do not effectively manage Robocath’s robotic systems and disposable products business

following the completion of the acquisition.

a result of the acquisition, we will be managing Robocath’s ongoing business of manufacturing, commercializing, developing and

selling robotic systems and associated disposable products and services. The manufacturing and development process of such robotic systems

and disposable products is complex, highly technical, and our prior experience in this field is dated. The process can be subject to

periodic worldwide supply chain disruptions, including labor shortages and inflationary pressures, and logistics delays which make it

difficult for us to source parts and ship our products. We may require a higher level of overhead than currently anticipated. Our ability

to successfully manage this new aspect of our business will depend, in part, upon management’s ability to design and implement

strategic initiatives that address not only the integration of Robocath into us, but also the increased scope of the combined business

with its associated increased costs and complexity. There can be no assurances that we will be successful in manufacturing and commercializing

Robocath’s robotic systems and disposable products or that we will realize the expected operating efficiencies, cost savings and

other benefits anticipated from the acquisition.

The

issuance of the earnout consideration using Earnout Shares will result in dilution to our stockholders and may adversely affect us, including

the market price of our securities.

the closing of the acquisition of Robocath on July 7, 2026, we issued 6,269,628 shares of our common stock as Closing Shares (including

shares of common stock issuable upon exercise of Purchaser Warrants issued to certain of the Selling Stockholders in lieu of Closing

Shares and 225,000 shares of common stock issued to Robocath’s financial advisor as partial payment of a success fee for acquisition

advisory services rendered to Robocath and its securityholders in connection with the Acquisition). In addition, the Share Sale Agreement

requires us to pay up to $25 million of additional earnout consideration to the Selling Stockholders upon achievement of the Regulatory

Milestone and/or the Commercial Milestones, which we may pay in cash, by issuing Earnout Shares (including shares of common stock issuable

upon exercise of Purchaser Warrants issued to certain of the Selling Stockholders in lieu of Earnout Shares), or in a combination of

cash and Earnout Shares (or Purchaser Warrants), at our election.

The

Share Sale Agreement obligated us to file a resale registration statement (of which this prospectus is a part) relating to the 6,269,628

Closing Shares and to Earnout Shares that may be issuable pursuant to the earnout provisions in the Share Sale Agreement. We have elected

to register 13,179,975 of such Earnout Shares; however, the exact number of shares we may

issue under the Share Sale Agreement as earnout consideration will depend on: (i) whether and to what extent the Regulatory and/or the

Commercial Milestones are achieved; (ii) whether we elect to pay all or a portion of such consideration in cash or using Earnout Shares

(or Purchaser Warrants); and (iii) the actual average closing price of our common stock calculated pursuant to a formula near the time

such milestones are achieved. The Share Sale Agreement provides for a cap on the number of Earnout Shares, when combined with the Closing

Shares, of 19.9% of the total number of shares of our common stock issued and outstanding as of July 7, 2026, which is approximately

the number of Earnout Shares covered by this prospectus.

a result of the foregoing, if the Regulatory and/or Commercial Milestones are achieved, we could elect to issue all of the Earnout

Shares in addition to the Closing Shares we issued at the closing of the Acquisition, which would cause significant additional

dilution to the Company’s stockholders. Moreover, even if we are not required to issue any Earnout Shares, the potential for the

issuance of such shares may negatively affect the trading price of our common stock in anticipation of such potential dilution. Sales

of a substantial number of shares comprising the Closing Shares or any Earnout Shares in the public market, or the perception that such

sales may occur, could adversely affect the market price of our securities.

Under

certain circumstances, we may take certain actions to achieve the milestones under the Share Sale Agreement that we would not have undertaken

if we had not completed the acquisition, which may have an adverse effect on the historical business of Stereotaxis.

particular, during the earnout periods under our Share Sale Agreement, which include a regulatory milestone period ending on December

31, 2033 and two commercial milestone periods ending on December 31, 2035 and December 31, 2037, respectively, we agreed to use commercially

reasonable efforts (as defined in the Share Sale Agreement) to complete the development of Robocath’s next-generation R-Two Products,

including product development, manufacturing, and clinical and regulatory efforts to obtain FDA regulatory approval and regulatory authorization

in Europe, and, subject to obtaining such authorizations, to commercialize the R-Two Products in the applicable territories. We also

agreed to use commercially reasonable efforts to retain Robocath employees, on an employment or consulting basis, necessary to achieve

the regulatory and commercial milestones and to ensure such individuals have adequate means, resources and support to perform their duties

effectively.

While

we retain the sole authority to operate and control Robocath’s business and its operations, including without limitation, any and

all decisions relating to various aspects of the combined business, we may nevertheless take certain actions related to the milestones

that we would not have undertaken if we had not completed the acquisition.

Robocath

has historically been a private company that prepared its financial statements in accordance with French GAAP and was not subject to

SEC reporting obligations, and we may encounter significant difficulties in integrating Robocath’s financial reporting and internal

controls with our own.

Prior

to our acquisition, Robocath was not required to maintain the financial reporting processes, internal controls over financial reporting,

or public company governance practices that are required of U.S. public companies. Developing and managing these processes at Robocath,

including the preparation of timely and accurate financial information for inclusion in our SEC filings and the implementation of internal

controls, procedures, and policies appropriate for a U.S.-based public company, will require significant management attention, resources

and expenditures. In addition, Robocath has historically prepared its financial statements in accordance with French generally accepted

accounting principles, which differ in significant respects from U.S. GAAP. The conversion of Robocath’s historical financial data

and ongoing accounting practices to U.S. GAAP may present substantial challenges, and we may encounter difficulties in identifying and

correcting deficiencies in Robocath’s internal controls over financial reporting that arise from these differences in accounting

standards and practices. Any failure to successfully convert Robocath’s financial data and accounting practices to U.S. GAAP, or

to establish and maintain adequate financial reporting processes and internal controls at Robocath, could result in material weaknesses

or significant deficiencies in our internal controls over financial reporting, errors or delays in our consolidated financial reporting,

restatements of our consolidated financial statements, additional audit costs, regulatory scrutiny, or increased legal or financial risk,

any of which could have a material adverse effect on our business, financial condition and results of operations.

French

labor and employment laws applicable to Robocath’s employees may increase our operational costs and adversely affect our business.

All

of the employees of our subsidiary, Robocath, are employed outside the United States, including in France, where labor and employment

laws are relatively stringent and, in many cases, grant significant job protection to certain employees, including rights upon termination

of employment. In addition, Robocath’s employees may be members of unions or represented by a works council as required by applicable

French law, and we may be required to consult with such unions or works councils in connection with certain operational decisions. These

more stringent labor and employment laws, to the extent that they are applicable, coupled with any requirement to consult with the relevant

unions or works councils, could increase our operational costs with respect to our employees at Robocath. If such increased operational

costs become significant, our business, financial condition, and results of operations could be adversely affected, perhaps materially.

may face significant tax risks and uncertainties in connection with Robocath’s operations, including challenges relating to transfer

pricing, withholding taxes, and local tax compliance.

Robocath’s

operations are subject to French corporate income tax, local business taxes and various other French and EU taxes. Following the acquisition,

intercompany transactions between Robocath and our US operations may be subject to complex transfer pricing rules, which require that

such transactions be conducted at arm’s length. In addition, dividends, interest, and other payments to us by Robocath may be subject

to French withholding taxes, potentially subject to reduction under the US-France tax treaty. Our limited experience with French tax

compliance and intercompany pricing increases the risk of disputes, adjustments, or penalties that could adversely affect our financial

results.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 18

v3.26.1

Cover

Jul. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 15, 2026

Entity File Number

001-36159

Entity Registrant Name

STEREOTAXIS,

INC.

Entity Central Index Key

0001289340

Entity Tax Identification Number

94-3120386

Entity Incorporation, State or Country Code

Entity Address, Address Line One

710

North Tucker Boulevard

Entity Address, Address Line Two

Suite 110

Entity Address, City or Town

St. Louis

Entity Address, State or Province

Entity Address, Postal Zip Code

63101

City Area Code

(314)

Local Phone Number

678-6100

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

STXS

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration